ArticleLaryngoscope investigative otolaryngology2026
Efficacy of Aspirin Usage in Free Flap Reconstruction of the Head and Neck.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare head and neck free flap outcomes and complications following aspirin administration. Methods: This is a multicenter, retrospective cohort study using data from the 107 healthcare organizations in the United States. Adult patients (≥ 18 years) with a history of head and neck cancer who received non-bony or bony free flap reconstruction were included. They were grouped by receiving 81 mg of aspirin (ASA81), 325 mg of aspirin (ASA325), or no aspirin on the same day of surgery or postoperatively. Primary outcomes included free flap failure, blood vessel repair, and need for flap revision. Relative risks (RR) with 95% confidence intervals (95% CI) were evaluated. Subgroup analysis was conducted between ASA81 and ASA325. Results: No differences in primary outcomes were observed for same day administration of aspirin. Postoperatively, ASA81 reduced the risk of flap failure and needing a blood vessel repair procedure (RR: 0.65[0.49-0.86]; 0.52[0.42-0.65]). ASA325 was also associated with a decreased risk of flap failure, need for blood vessel repair, and the need for flap revision procedures (RR: 0.10[0.08-0.13]; 0.57[0.46-0.71]; 0.37[0.32-0.41]) for all flap types. For non-bony reconstruction, all primary outcomes were lower in the ASA81 group (RR: 0.72[0.53-0.98]; 0.53[0.41-0.68]; 0.73[0.59-0.89]). ASA325 for non-bony flaps was also associated with lower rates of all three primary outcomes (RR: 0.47[0.34-0.64]; 0.63[0.49-0.80]; 0.80[0.68-0.94]). Aspirin use in bony flaps was associated with similar outcomes. ASA81 compared to ASA325 for non-bony reconstruction was associated with higher flap failure (RR: 1.69[1.16-2.46]). Conclusion: For non-bony and bony free flap reconstruction, aspirin was associated with decreased risks of free flap failure, blood vessel repair, and flap revision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.